Dermavant Sciencesan Organon Companyis A Biotechnology Firm Focused On Immuno Dermatologythe Company Specializes In Developing Innovative Therapies For Chronic Skin Conditionsparticularly Plaque Psoriasis And Atopic Dermatitisacquired By Organon In October 2024Dermavant Aims To Address Unmet Medical Needs In Dermatology Through Efficient Research And Clinical Development Dermavant S Flagship Product Is Vtamaa Tapinarofcreamwhich Is Fda Approved For Treating Mild To Severe Plaque Psoriasis In Adultsthe Company Is Also Advancing Its Pipeline With Promising Results In Atopic Dermatitis And Developing Dmvt 506A Next Generation Treatment For Inflammatory Diseaseswith A Commitment To Patient Centric Innovationdermavant Seeks To Redefine Standards Of Care In Dermatology Through Scientifically Validated Therapiesthe Company Operates With A Team Of 201Ae 500 Employeesprimarily Based In Californiaand Utilizes Advanced Tools For Data Analytics And Clinical Research
